Evidence map›Paper›PMID 15883813›Full record

ArticleJournal of cancer research and clinical oncology2005

Suppressing effects of daily oral supplementation of beta-glucan extracted from Agaricus blazei Murill on spontaneous and peritoneal disseminated metastasis in mouse model.

Hiroshi Kobayashi, Ryuji Yoshida, Yasufumi Kanada, Yoichi Fukuda, Tatsuo Yagyu, Kiyokazu Inagaki, Toshiharu Kondo, Noriyuki Kurita, Mika Suzuki, Naohiro Kanayama and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Integrative Medicine for Ovarian Cancer.Current oncology reports · 2023
    Review
  7. Review
  8. Review
  9. Review
  10. Effects of Medicinal Fungi-Derived β-Glucan on Tumor Progression.Journal of fungi (Basel, Switzerland) · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Hiroshi KobayashiDepartment of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Handayama 1-20-1, Hamamatsu, Shizuoka 431-3192, Japan. hirokoba@hama-med.ac.jp
Ryuji Yoshida
Yasufumi Kanada
Yoichi Fukuda
Tatsuo Yagyu
Kiyokazu Inagaki
Toshiharu Kondo
Noriyuki Kurita
Mika Suzuki
Naohiro Kanayama
Toshihiko Terao
Hamamatsu University School of Medicine · JPFuji Oil (Japan) · JPToyohashi University of Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe Basidiomycete fungus Agaricus blazei Murill has traditionally been used as a health food for the prevention of cancer.

methodsWe examined whether beta-(1-6)-D: -glucan extracted from A. blazei is a potential anticancer agent in an in vitro and in vivo animal model.

resultsHere we show that (1) beta-glucan had cytotoxic effect against human ovarian cancer HRA cells, but not against murine Lewis lung cancer 3LL cells, in vitro; (2) beta-glucan promotes p38 MAPK activity for suppressing HRA cell proliferation and amplifying the apoptosis cascade; (3) beta-glucan stimulates translocation of the proapoptotic protein, Bax, from the cytosol to mitochondria, cytochrome c release, and subsequent caspase-9 activation; (4) treatment with SB203580, a p38 MAPK-specific inhibitor, suppresses beta-glucan-induced effects, indicating that activation of p38 MAPK is involved in the suppression of cell proliferation and mitochondrial activation-mediated cell death pathway; (5) in mice, oral supplementation with beta-glucan reduces pulmonary metastasis of 3LL cells and peritoneal disseminated metastasis of HRA cells and inhibits the growth of these metastatic tumors in lung or peritoneal cavity, in part, by suppressing uPA expression; and (6) in an in vivo experimental metastasis assay, however, the oral supplementation with beta-glucan after i.v. tumor cell inoculation did not reduce the number of lung tumor colonies.

conclusionTreatment with beta-glucan may be beneficial for cancer patients with or at risk for metastasis. The beta-glucan-dependent signaling pathways are critical for our understanding of anticancer events and development of cancer therapeutic agents.

Indexed as

Administration, OralAgaricusAnimalsAntineoplastic AgentsApoptosisbeta-GlucansCarcinoma, Lewis LungCell ProliferationDrug Administration ScheduleEnzyme ActivationFemaleHumansMiceOvarian Neoplasmsp38 Mitogen-Activated Protein KinasesPeritoneal NeoplasmsAntineoplastic Agentsbeta-1,6-glucanbeta-Glucansp38 Mitogen-Activated Protein Kinases

Identifiers

PMID15883813
PMCPMC12161265
OpenAlexW2018983078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.